Why the study?
ECMO represents a therapeutic option for cardiopulmonary support in high-risk pulmonary embolism, but no definite consensus exists regarding its use.
What are the clinical outcomes and adverse events associated with ECMO use in patients with high-risk acute pulmonary embolism?
What are the clinical outcomes and adverse events associated with ECMO use in patients with high-risk acute pulmonary embolism?
In patients with high-risk pulmonary embolism, ECMO support is associated with an early all-cause mortality of 41.1% and a major bleeding rate of 28.6%.
Answers are grounded in this paper and cite their sources.
High early mortality with ECMO in high-risk PE warrants caution; leaves open optimal selection and RCTs to define benefit.
Extracorporeal membrane oxygenation (ECMO) represents a therapeutic option for cardiopulmonary support in patients with high-risk pulmonary embolism (PE); however, no definite consensus exists on ECMO use in high-risk PE. Hence, we aim to provide insights into its real-world use pooling together all available published experiences. We performed a systematic review and pooled analysis of all published studies (up to April 17, 2020) investigating ECMO support in high-risk PE. All studies including at least four patients were collectively analyzed. Study outcomes were early all-cause death (primary endpoint) and relevant in-hospital adverse events. A total of 21 studies were included in the pooled analysis (n = 635 patients). In this population (mean age 47.8 ± 17.3 years, 44.5% females), ECMO was indicated for cardiac arrest in 62.3% and immediate ECMO support was pursued in 61.9% of patients. Adjunctive reperfusion therapies were implemented in 57.0% of patients. Pooled estimate rate of early all-cause mortality was 41.1% (95% CI 27.7%-54.5%). The most common in-hospital adverse event was major bleeding, with an estimated rate of 28.6% (95%CI 21.0%-36.3%). At meta-regression analyses, no significant impact of multiple covariates on the primary endpoint was found. In this systematic review of patients who received ECMO for high-risk PE, pooled all-cause mortality was 41.1%. Principal indication for ECMO was cardiac arrest, cannulation was chiefly performed at presentation, and major bleeding was the most common complication.
No takes yet. Share an insight, caveat, or question.
Baldetti et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: